FCGR3A and neuroblastoma: In contrast to the LTI study (13), in our cohort, haplo HSCT using donors with high affinity FcGR3A or FcGR2A did not have any impact on event-free survival and overall survival in neuroblastoma Stage IV relapsed patients with subsequent GD2 targeted ch14.18/CHO antibody therapy.